Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
.
Item in Clipboard
J Neurol. 2021 Sep 4:1-14. doi: 10.1007/s00415-021-10780-7. Online ahead of print. J Neurol. 2021. PMID: 34480607 .